Fast Market Research

Rheumatoid Arthritis - Pipeline Review, H1 2014: New Research Report Available at Fast Market Research

Fast Market Research recommends "Rheumatoid Arthritis - Pipeline Review, H1 2014" from Global Markets Direct, now available

 
Repost This

Boston, MA -- (SBWIRE) -- 04/16/2014 -- Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H1 2014', provides an overview of the Rheumatoid Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rheumatoid Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis and special features on late-stage and discontinued projects.

View Full Report Details and Table of Contents

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rheumatoid Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned in this Report: Alcon, Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Inovio Pharmaceuticals, Inc., MedImmune, LLC, Isis Pharmaceuticals, Inc., Gilead Sciences, Inc., Biotest AG, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Ablynx NV, AbGenomics International, Inc., Emergent BioSolutions Inc., Novo Nordisk A/S, Infinity Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Plexxikon Inc., ViaCord, LLC, arGentis Pharmaceuticals, LLC, Reliance Life Sciences Pvt. Ltd., MediGene AG, Celltrion, Inc., TiGenix NV, Pacira Pharmaceuticals, Inc., Hanwha Chemical Corporation, Astellas Pharma Inc., Biocon Limited, Chugai Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Richter Gedeon Nyrt., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Pfizer Inc., Ranbaxy Laboratories Limited, Rigel Pharmaceuticals, Inc., Salix Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, Toyama Chemical Co., Ltd., UCB S.A., Vertex Pharmaceuticals Incorporated, Zydus Cadila Healthcare Limited, Cell Therapeutics, Inc., Hadasit Medical Research Services & Development Ltd, Sandoz Inc., Paratek Pharmaceuticals, Inc., CEL-SCI Corporation, Celgene Corporation, Onyx Pharmaceuticals, Inc., Incyte Corporation, OPKO Health, Inc., XTL Biopharmaceuticals Ltd., Bone Medical Limited, 4SC AG, Addex Therapeutics, EntreMed, Inc., Harbor Therapeutics, Inc., Can-Fite BioPharma Ltd., Idera Pharmaceuticals, Inc., Karo Bio AB, Ligand Pharmaceuticals, Inc., Almirall, S.A., Lupin Limited, Mesoblast Limited, Bionomics Limited, Swedish Orphan Biovitrum AB, Nutra Pharma Corporation, Nuvo Research Inc., Compugen Ltd., Orchid Chemicals & Pharmaceuticals Ltd, Lexicon Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Yuhan Corporation, Regeneron Pharmaceuticals, Inc., Pharmacyclics, Inc., Protalix BioTherapeutics, Inc., Tolerx, Inc., Handok Inc., Boryung Pharmaceutical Co., Ltd., Green Cross Corporation, HanAll Biopharma Co., Ltd., Nichi-Iko Pharmaceutical Co., Ltd., LG Life Sciences, Ltd., Biotie Therapies Corp., Galapagos NV, Synta Pharmaceuticals Corp., Panacea Biotec Limited, CrystalGenomics, Inc., Sareum Holdings plc, Protalex, Inc., Innate Pharma SA, DiaMedica Inc., Myungmoon pharmaceutical Co.,Ltd., Intas Pharmaceuticals Ltd., Morphotek, Inc., Spectrum Pharmaceuticals, Inc., Chroma Therapeutics Ltd., Advinus Therapeutics Ltd., Auspex Pharmaceuticals, Inc., Scynexis, Inc., Affimed Therapeutics AG, Axxam SpA, Chipscreen Biosciences Ltd, CIMAB S.A., AcurePharma AB, Ambit Biosciences Corporation, Immupharma Plc, Upsher-Smith Laboratories, Inc., Palau Pharma, S.A., Farmacija d.o.o. Tuzla, Acceleron Pharma, Inc., Phenex Pharmaceuticals AG, Neovacs SA, Hutchison MediPharma Limited, Viropro Inc., ugichem GmbH, Aegera Therapeutics Inc., Amura Holdings Ltd., Anacor Pharmaceuticals, Inc., Alder Biopharmaceuticals Inc., IMMD Inc., Coronado Biosciences, Inc., Funxional Therapeutics Ltd, MacroGenics, Inc., Antyra, Inc., Recoly N.V., Therametrics holding AG, Opsona Therapeutics Ltd., Asahi Kasei Pharma Corp., Five Prime Therapeutics, Inc., Vaccinex, Inc., Syntrix Biosystems, Inc., Kineta, Inc., Alloksys Life Sciences BV, MSM Protein Technologies, Inc., Vascular Biogenics Ltd., NovImmune SA, TxCell SA, Endocyte, Inc., Theraclone Sciences, Inc., Theracos, Inc., Effimune SAS, Cardax Pharmaceuticals, Inc., CG Pharmaceuticals, Inc., Kainos Medicine, Inc., Karus Therapeutics Limited, Omeros Corporation, Y's Therapeutics Co., Ltd., Xencor, Inc., Cornerstone Therapeutics Inc., Onepharm Research and Development GmbH, Acetylon Pharmaceuticals, Inc., ChemoCentryx, Inc., Cellceutix Corporation, AB Science, Provid Pharmaceuticals, Inc., Vitae Pharmaceuticals, Inc., Biokine Therapeutics Ltd., OncoImmune, Inc., Avesthagen Limited, KAHR medical Ltd., SuppreMol GmbH, ViroMed Co., Ltd., Ferring Pharmaceuticals, Inc., CLL Pharma, Covagen AG, Domainex Ltd., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Dynamix Pharmaceuticals Ltd., Amplimmune, Inc., Lycera Corp., Ohr Pharmaceutical Inc., ImmunoFrontier, Inc., Pepscan Therapeutics, ModiQuest B.V., Motif BioSciences, Inc., Pfenex Inc., Mycenax Biotech Inc., Biosidus S.A., Cellmid Limited, Genosco, Mebiopharm Co., Ltd., Vichem Chemie Research Ltd., Mabion SA, Diurnal Ltd, Fountain Biopharma Inc., Serodus ASA, Adiga Life Sciences Inc., Genor BioPharma Co., Ltd., Oneness Biotech Co., Ltd., Aprogen, Inc., RedHill Biopharma Ltd., Selvita S.A, ProNoxis AB, ProtAb Ltd, Complix NV, PurGenesis Technologies Inc., Apexigen, Inc., Arthrogen BV, Ensemble Therapeutics Corporation, Kadmon Pharmaceuticals, LLC, Inbiopro Solutions Pvt. Ltd., Shanghai Pharmaceuticals Holding Co Ltd, Hanmi Pharmaceuticals, Co. Ltd., R-Pharm, Avexxin AS, Griffin Discoveries BV, Immune Response BioPharma, Inc., Aslan Pharmaceuticals Pte. Ltd., Cellworks Group, Inc., MENTRIK Biotech, LLC, Visionary Pharmaceuticals, Inc., Arrien Pharmaceuticals, LLC, Allinky Biopharma, Qu Biologics Inc., Oncobiologics, Inc., Rhizen Pharmaceuticals SA, bioXPRESS Therapeutics SA, Avipep Pty Ltd, ReveraGen BioPharma, Inc., InvivoGen Therapeutics, Biocad, Innovent Biologics, Inc., AbbVie Inc., L2 Diagnostics LLC, Peptinnovate Limited, TechnoPhage SA, ChironWells GmbH, Toleranzia AB, Pharmedartis GmbH, vida therapeutics inc., AlphaMab Co., Ltd, TheraMAB LLC., Paras Biopharmaceuticals Finland Oy, Medac Pharma, Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Arthritis - Pipeline Review, H1 2014
- Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014
- Osteoarthritis - Pipeline Review, H1 2014
- Parkinson's Disease - Pipeline Review, H1 2014
- Alzheimer's Disease - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Type 2 Diabetes - Pipeline Review, H1 2014
- Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
- Hepatitis C - Pipeline Review, H1 2014
- Neuropathic Pain - Pipeline Review, H1 2014